PT  - JOURNAL ARTICLE
AU  - Yates, Jennifer L.
AU  - Ehrbar, Dylan J.
AU  - Hunt, Danielle T.
AU  - Girardin, Roxanne C.
AU  - Dupuis, Alan
AU  - Payne, Anne F.
AU  - Sowizral, Mycroft
AU  - Varney, Scott
AU  - Kulas, Karen E.
AU  - Demarest, Valerie L.
AU  - Howard, Kelly M.
AU  - Carson, Kyle
AU  - Hales, Margaux
AU  - Ejemel, Monir
AU  - Li, Qi
AU  - Wang, Yang
AU  - Mantis, Nicholas J.
AU  - McDonough, Kathleen A.
AU  - Lee, William T.
TI  - Serological Analysis Reveals an Imbalanced IgG Subclass Composition Associated with COVID-19 Disease Severity
AID  - 10.1101/2020.10.07.20208603
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.07.20208603
4099  - http://medrxiv.org/content/early/2020/10/09/2020.10.07.20208603.short
4100  - http://medrxiv.org/content/early/2020/10/09/2020.10.07.20208603.full
AB  - COVID-19 is associated with a wide spectrum of disease severity, ranging from asymptomatic to acute respiratory distress syndrome (ARDS). Paradoxically, a direct relationship has been suggested between COVID-19 disease severity, and the levels of circulating SARS-CoV-2-specific antibodies, including virus neutralizing titers. Through a serological analysis of serum samples from 536 convalescent healthcare workers, we found that SARS-CoV-2-specific and virus-neutralizing antibody levels were indeed elevated in individuals that experienced severe disease. The severity-associated increase in SARS-CoV-2-specific antibody was dominated by IgG, with an IgG subclass ratio skewed towards elevated receptor binding domain (RBD)- and S1-specific IgG3. However, RBD- and S1-specific IgG1, rather than IgG3 were best correlated with virus-neutralizing titers. We propose that Spike-specific IgG3 subclass utilization contributes to COVID-19 disease severity through potent Fc-mediated effector functions. These results have significant implications for SARS-CoV-2 vaccine design, and convalescent plasma therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was performed in part under a Project Award Agreement from the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and financial assistance award 70NANB20H037 from the U.S. Department of Commerce, National Institute of Standards and Technology. A portion of the work described in this publication was supported by Cooperative Agreement Number NU50CK000516 from the Centers of Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Wadsworth Center IRB Approval 20-021.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used in the manuscript is not publicly available.